Neuroscientific Biopharmaceuticals Ltd has released a press release.
Investor Update Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Neuroscientific Biopharmaceuticals
- CEO Resignation
- HREC decision to not approve Phase I Clinical Trial
- 2022 Annual Report and Appendix 4E
- NeuroScientific releases FY2022 Results
- HREC Submission for Phase I Clinical Trial
Later from Neuroscientific Biopharmaceuticals
- Appointment of Interim CEO
- NSB files new patent
- R&D Tax Incentive Refund Received
- Positive treatment effect in MS animal study
- 2023 Annual Report and Appendix 4E
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals